An Open-label, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms Study 217
- Sponsors Eisai Co Ltd
- 26 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 29 Feb 2016 According to an Eisai media release, based on the results of this trial, eribulin mesylate (Halaven) received approval in Japan for use in the treatment of patients with soft tissue sarcoma.
- 15 Jul 2014 Planned End Date changed from 1 Jan 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov.